COCP 2,09$ (+56%)

“We believe that, due to their novel mechanism of action, our protease inhibitors are likely to be effective against new variants of SARS-CoV-2. This may include the recent variants first identified in the United Kingdom, South Africa, Brazil and India, which may be more contagious forms of the virus and may evade immunity produced by vaccines or previous infection,” he added.

... Cocrystal’s approach to drug discovery could provide a solution for designing antivirals for use against a range of viruses, including coronaviruses, with limited off-target interaction.  

Cocrystal Pharma Announces $40 Million Bought Deal Offering of Common Stock

... 26,000,000 shares of common stock of the Company, at a price to the public of $1.54 per share, less underwriting discounts and commissions. The closing of the offering is expected to occur on or about May 7, 2021, subject to satisfaction of customary closing...

https://finance.yahoo.com/news/...announces-40-million-224100461.html

 

Cocrystal Pharma’s SARS-CoV-2 3CL Protease Lead CDI-45205 Demonstrates Broad-Spectrum Activity Against the SARS-CoV-2 Delta and Gamma Variants

https://www.cocrystalpharma.com/news/...2-3cl-protease-lead-cdi-45205  

20.08.21:
40.000 shares zu $1.03

http://www.insidercow.com  

Cocrystal Pharma Receives Australian Regulatory Clearance to Initiate Phase 1 Study of CC-42344 for the Treatment of Pandemic and Seasonal Influenza

https://finance.yahoo.com/news/...ustralian-regulatory-124900491.html  

 

Cocrystal Pharma’s SARS-CoV-2 Main Protease Inhibitors Demonstrate Pan-viral Activity against Human Common Coronaviruses, Noroviruses, Rhinoviruses, and Enteroviruses

…SARS-CoV-2 main protease inhibitors showed potent in vitro pan-viral activity against human common coronaviruses, rhinoviruses, and respiratory enteroviruses that frequently cause the common cold, as well as against noroviruses that can cause symptoms of acute gastroenteritis.

…Our current focus is on advancing these SARS-CoV-2 main protease inhibitors toward clinical development as a potential oral treatment for patients with COVID-19,” he added. “We now have additional opportunities with these same protease inhibitors for future programs that target other areas of high unmet medical need.”

https://www.cocrystalpharma.com/news/...ov-2-main-protease-inhibitors  

Vom 22.12.2021

Cocrystal Pharma’s COVID-19 Oral and Intranasal/Pulmonary Protease Inhibitors Exhibit Powerful In Vitro Potency Against the SARS-CoV-2 Omicron Variant

...We believe that, due to their novel mechanism of action, our protease inhibitors will be effective against newly emerging SARS-CoV-2 variants. We are also highly encouraged by promising safety profiles of our SARS-CoV-2 oral protease inhibitors from 7-day mouse oral dosing toxicity studies. Our goal is to rapidly advance two protease inhibitors into first-in-human studies as rapidly as possible.”

https://www.cocrystalpharma.com/news/...-oral-and-intranasalpulmonary  

ocrystal Pharma Receives FDA Guidance to Advance Clinical Development of its COVID-19 Antiviral CDI-45205

BOTHELL, Wash., Jan. 06, 2022 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”) announces receipt of guidance from the U.S. Food and Drug Administration (FDA) for the further development of CDI-45205, Cocrystal’s novel SARS-CoV-2 main protease inhibitor as a potential treatment for COVID-19 and its variants via intranasal/pulmonary delivery. The FDA’s guidance was received in a written response to Cocrystal’s pre-Investigational New Drug (IND) briefing package that was submitted in October 2021.

“The FDA’s response contained extensive and valuable responses to a list of questions we proposed in our pre-IND briefing package, providing key insights on advancing the non-clinical and clinical development of CDI-45205,” said Sam Lee, Ph.D., President and interim co-CEO of Cocrystal. “The FDA’s guidance marks an important milestone in our continued development of CDI-45205. We now have a clearer pathway for our planned Phase 1 single-ascending-dose and multiple-ascending-dose study that we expect to initiate in 2022, as well as directives for designing a subsequent Phase 2 study.”

The FDA’s response covered topics including preclinical studies, manufacturing, pharmacology and toxicology, and clinical development plans for CDI-45205 for Phase 1 and Phase 2 studies. In preparation for clinical development, Cocrystal intends to conduct CDI-45205 formulation development, IND-enabling studies and virology assessments, as well as API drug manufacturing for use in preclinical and clinical studies.

CDI-45205 is one of three COVID-19 programs underway at Cocrystal. In the second COVID-19 program, the Company plans to begin a Phase 1 study also in 2022 with an orally administered main protease inhibitor. In the third COVID-19 program, Cocrystal is using its unique structure-based technology platform to discover replication inhibitors for oral administration.

“Our COVID-19 programs feature novel inhibitors that are specifically designed to block viral replication of SARS-CoV-2,” said James Martin, Cocrystal’s CFO and interim co-CEO. “Our inhibitors have shown antiviral activity against various SARS-CoV-2 variants to date, including the Alpha, Beta, Gamma and Delta variants, and now even the Omicron variant. CDI-45205 is not a quick-to-market repurposed drug. Because of its design, we remain highly confident in the broad-spectrum antiviral ability of our compound CDI-45205 in addressing SARS-CoV-2 and variants.”

https://www.cocrystalpharma.com/news/...-guidance-to-advance-clinical  

Cocrystal Pharma Selects Two Lead Antiviral Drug Candidates for its COVID-19 Oral Drug Program

•Novel broad-spectrum oral lead candidates CDI-988 and CDI-873, discovered using Cocrystal’s antiviral drug discovery platform, demonstrate superior in vitro potency against SARS-CoV-2 and activity against all variants of concern including Omicron

•Clinical trials with oral program and CDI-45204 inhalation/pulmonary-delivered COVID-19 antiviral candidates expected to begin in 2022

https://ir.cocrystalpharma.com/press-releases/...iral-drug-candidates  

Studie
https://ir.cocrystalpharma.com/press-releases/detail/152  

https://ir.cocrystalpharma.com/press-releases/detail/157